IP Library Granted Patent US 8,148,528
Granted Patent B2
US 8,148,528 · App. 12/469,951 · Granted Apr 3, 2012

Processes and compounds for the preparation of normorphinans

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,148,528
App. No.
12/469,951
Granted
Apr 3, 2012
Kind
B2
Abstract

The invention generally provides processes and intermediate compounds useful for the production of normorphinans and derivatives of normorphinans.

Claims (42)

1. A compound comprising of Formula 21a:

wherein:

R 1 and R 2 are independently chosen from hydrogen, OH, NH 2 , SH, CF 3 , hydrocarbyl, substituted hydrocarbyl, alkyl ketal, alkyl thiol ketal, and alkyl dithiol ketal, wherein when R 1 and R 2 are different they form an epimeric pair, and wherein R 1 and R 2 together may form a group chosen from =0, ═S, cycloalkyl ketal, cycloalkyl thiol ketal, and cycloalkyl dithiol ketal;

R 3 is chosen from hydrogen, halogen, OH, NH 2 , CN, CF 3 , SO 2 R 8 , hydrocarbyl, and substituted hydrocarbyl;

R 4 and R 5 are independently chosen from —(CH 2 ) n CH 3 and CH 3 ;

R 8 is chosen from hydrocarbyl and substituted hydrocarbyl;

X is halogen;

Y is chosen from a benzyloxycarbonyl group, an alkylamidocarbonyl group, a trialkylsilyl group, an alkylsulfonyl group, and an aryl sulfonyl group; and

n is an integer from 1 to 8.

2. The compound of claim 1 , wherein:

R 1 , R 2 , and R 3 are each hydrogen;

R 4 and R 5 are each CH 3 ;

X is bromine; and

Y is chosen from —Si(CH 3 ) 3 , and —SO 2 CH 3 .

3. The compound of claim 1 , wherein the optical activity of the compound is (+) or (−), and the configuration of C-5, C-13, and C-9, respectively, of the compound may be RRR, RRS, RSR, RSS, SRR, SRS, SSR, or SSS, provided that the C-15 and the C-16 carbons are both either on the alpha face or the beta face of the molecule.

4. A process for the preparation of compound 21a, the process comprising the following reaction scheme:

wherein:

R 1 and R 2 are independently chosen from hydrogen, OH, NH 2 , SH, CF 3 , hydrocarbyl, substituted hydrocarbyl, alkyl ketal, alkyl thiol ketal, and alkyl dithiol ketal, wherein when R 1 and R 2 are different they form an epimeric pair, and wherein R 1 and R 2 together may form a group chosen from =0, ═S cycloalkyl ketal, cycloalkyl thiol ketal, and cycloalkyl dithiol ketal;

R 3 is chosen from hydrogen, halogen, OH, NH 2 , CN, CF 3 , SO 2 R 8 , hydrocarbyl, and substituted hydrocarbyl;

R 4 and R 5 are independently chosen from —(CH 2 ) n CH 3 , and CH 3 ;

R 8 is chosen from hydrocarbyl and substituted hydrocarbyl;

X and X 1 are independently halogen;

Y is chosen from a benzyloxycarbonyl group, an alkylamidocarbonyl group, a trialkylsilyl group, an alkylsulfonyl group, and an aryl sulfonyl group;

m is an integer from 1 to 3; and

n is an integer from 1 to 8.

5. The process of claim 4 , wherein:

YX is chosen from (CH 3 ) 3 SiCl, POCl 3 , and CH 3 SO 2 Cl;

R 1 , R 2 , and R 3 are each hydrogen;

R 4 and R 5 are each CH 3 ; and

X 1 is bromine.

6. The process of claim 4 , wherein the molar/molar ratio of compound 20 to YX is from about 1:1 to about 1:50, the reaction is conducted in the presence of an aprotic solvent, and the reaction is conducted at a temperature ranging from about 0° C. to about 80° C.

7. The process of claim 4 , wherein the yield of compound 21 is from about 60% to about 90%.

8. The compound of claim 1 wherein Y is a benzyloxycarbonyl group.

9. The compound of claim 1 wherein Y is an alkylamidocarbonyl group.

10. The compound of claim 1 wherein Y is a trialkylsilyl group.

11. The compound of claim 1 wherein Y is an alkylsulfonyl group.

12. The compound of claim 1 wherein Y is an aryl sulfonyl group.

13. The process of claim 4 wherein Y is a benzyloxycarbonyl group.

14. The process of claim 4 wherein Y is an alkylamidocarbonyl group.

15. The process of claim 4 wherein Y is a trialkylsilyl group.

16. The process of claim 4 wherein Y is an alkylsulfonyl group.

17. The process of claim 4 wherein Y is an aryl sulfonyl group.

Assignments (15)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE SHOULD STATE MALLINCKRODT INC. INSTEAD OF MALLINCKRODT LLC PREVIOUSLY RECORDED ON REEL 032504 FRAME 0163. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNEE SHOULD STATE MALLINCKRODT INC. INSTEAD OF MALLINCKRODT LLC. Recorded Apr 8, 2014
From: WANG, PETER X.; MOSER, FRANK W.; CANTRELL, GARY L.; JIANG, TAO; HALVACHS, ROBERT E.; GROTE, CHRISTOPHER W.
To: MALLINCKRDOT INC.
Reel/Frame 032632/0921 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2014
From: WANG, PETER X.; MOSER, FRANK W.; CANTRELL, GARY L.; JIANG, TAO; HALVACHS, ROBERT E.; GROTE, CHRISTOPHER W.
To: MALLINCKRODT LLC
Reel/Frame 032504/0163 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →